Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial
about
Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort studyOptimal timing for antiretroviral therapy initiation in patients with HIV infection and concurrent cryptococcal meningitisThe 2015 Clinical Guidelines for the Treatment and Prevention of Opportunistic Infections in HIV-Infected Koreans: Guidelines for Opportunistic InfectionsThe role of infection in miscarriagePneumocystis Pneumonia in Human Immunodeficiency Virus-infected Adults and Adolescents: Current Concepts and Future DirectionsExtensive Central Nervous System Cryptococcal Disease Presenting as Immune Reconstitution Syndrome in a Patient with Advanced HIV: Report of a Case and Review of Management Dilemmas and StrategiesMissed opportunities for HIV testing and late-stage diagnosis among HIV-infected patients in UgandaUse of anti-retroviral therapy in tuberculosis patients on second-line anti-TB regimens: a systematic reviewTreatment of cryptococcal meningitis in KwaZulu-Natal, South Africa.Urinary Tract Infection among Antiretroviral Therapy Users and Nonusers in Jimma University Specialized Hospital, Jimma, Ethiopia.Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infectionLate presenters to HIV care and treatment, identification of associated risk factors in HIV-1 infected Indian population.Cryptococcal meningitis: epidemiology and therapeutic options.Highly active antiretroviral treatment for the prevention of HIV transmission.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS.When to start antiretroviral therapyEarly versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.Optimum timing of antiretroviral therapy for HIV-infected patients with concurrent serious opportunistic infections.Treatment outcomes in a decentralized antiretroviral therapy program: a comparison of two levels of care in north central Nigeria.Recent key advances in human immunodeficiency virus medicine and implications for ChinaThe prevalence and clinical course of HIV-associated pulmonary cryptococcosis in Uganda.Early HIV treatment in the United States prevented nearly 13,500 infections per year during 1996-2009Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.Survival outcomes and effect of early vs. deferred cART among HIV-infected patients diagnosed at the time of an AIDS-defining event: a cohort analysisUpdate on opportunistic infections in the era of effective antiretroviral therapyMagnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regionsClinical and immunologic predictors of death after an acute opportunistic infection: results from ACTG A5164.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theUsing CD4 percentage and age to optimize pediatric antiretroviral therapy initiationBrain magnetic resonance imaging screening is not useful for HIV-1-infected patients without neurological symptomsMycobacterial antigen driven activation of CD14++CD16- monocytes is a predictor of tuberculosis-associated immune reconstitution inflammatory syndromeEvolution of HIV treatment guidelines in high- and low-income countries: converging recommendationsAre plasma biomarkers of immune activation predictive of HIV progression: a longitudinal comparison and analyses in HIV-1 and HIV-2 infections?Timing of antiretroviral therapy for HIV in the setting of TB treatment.Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa.Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitionsCytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.Inpatient mortality of HIV-infected adults in sub-Saharan Africa and possible interventions: a mixed methods review
P2860
Q21144623-40654FB0-49F4-49E1-85A9-53EFA3AABD38Q24200929-071E1D21-DC3E-4722-9412-7FAAF0B1A864Q26751038-CCEF6461-08E2-4173-88E3-603520BD38C4Q26783142-BC84B960-1C71-4C73-A273-68919DD9C2A6Q26795592-864B2CE6-5EBB-4489-8F74-0D874D12EED0Q26852378-F9116D5F-1E7B-4221-A91F-5286127763F7Q28478923-BA48DC99-355D-4563-9CEA-7065595A4527Q28484857-6C774F7D-0AD7-4A67-8647-732B52E65366Q33523050-820F8251-30FA-4910-8A85-68BFA3F478B2Q33562961-A1E3FF65-2E96-4D15-AF17-107DDB28E34CQ33628799-CE98D250-846C-44BC-AFF8-EA5CFFA9F47BQ33631762-0423F3D3-CC02-4EF7-A77A-D7938960EE40Q33633343-2000C855-A9E5-4665-8B36-28B1427D32B2Q33657373-2ECBFB47-C4F3-42E8-BF7C-A4FB07C3469CQ33775397-B2C29C80-B4F7-4203-BFD6-8CC3B86FA6A3Q33790033-CBC36ECB-6F02-4F73-ABEB-5AB5FEE31E8CQ33799012-7D0A777D-0593-4C91-B597-E69A32E006CDQ33807615-2AD7D157-6560-4229-9780-2B67694638B0Q33823233-776A3B39-A0A2-462E-80D1-BD37CCB12589Q33852863-BDCB4E9A-9AFD-469D-BF8A-488AA0DA9ABEQ33933502-4C359F29-430F-40FE-B98D-887CF7494EDCQ33941330-D0870399-B2A3-429A-9402-59CB3BB1F3D9Q34014700-04443F11-677C-4D72-AAAE-DFA0C960A3EBQ34020746-56BFD41F-1D51-4DFF-9A36-7B6C4837D761Q34024416-CBFCAC6A-717E-42D6-9F8E-CCC3C7432C76Q34063630-DF796EBD-CB48-4F4D-80A2-B971F396FE6DQ34085853-9DFD5A81-B02B-40E0-B848-C2AA3DFCB56BQ34168721-ABD4C398-650F-4790-B9E8-7C27BE900C86Q34202331-268FDAEB-4C85-40AA-AE6B-B6BF10B166A0Q34212799-A1D2B7F6-0D18-4B4C-A186-25EB5969C420Q34263117-E9DF59CF-05E5-4B7C-81DD-BE1E738D1E10Q34267308-8BBF00C8-5688-454E-9B7A-927F30CD25BDQ34282914-D51F5E97-906B-4465-8101-C67F9E606BF7Q34321843-2D739D07-AE4A-416B-A13F-1EF58891E81CQ34412376-AF0EE9F3-5599-439E-9164-33287530E588Q34475542-D06FCDE8-58CB-4830-9E7B-52C66AC4E313Q34477198-A705930E-3451-4B5E-9E2C-A92E4CDE9B01Q34516548-184095E1-359C-4BC3-BF5B-56F21CC22128Q34670354-CD11E8F5-B950-4261-AE34-415F56FEF8F1Q34694867-A1E743A0-181D-405D-982E-DD20A090F730
P2860
Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Early antiretroviral therapy r ...... nter randomized strategy trial
@en
Early antiretroviral therapy r ...... ter randomized strategy trial.
@nl
type
label
Early antiretroviral therapy r ...... nter randomized strategy trial
@en
Early antiretroviral therapy r ...... ter randomized strategy trial.
@nl
prefLabel
Early antiretroviral therapy r ...... nter randomized strategy trial
@en
Early antiretroviral therapy r ...... ter randomized strategy trial.
@nl
P2093
P2860
P921
P1433
P1476
Early antiretroviral therapy r ...... nter randomized strategy trial
@en
P2093
Alejandro Sanchez
Andrew Zolopa
Carol Suckow
Evelyn Hogg
Janet Andersen
Lauren Komarow
William Powderly
P2860
P356
10.1371/JOURNAL.PONE.0005575
P407
P50
P577
2009-05-18T00:00:00Z